Novo Nordisk upgraded to Buy from Neutral at UBS
Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a ...
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
First Hawaiian Bank boosted its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 30.3% in the fourth ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...
International Assets Investment Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 98 ...
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.
Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback